For the quarter ending 2025-09-30, TELA had -$5,279K decrease in cash & cash equivalents over the period. -$5,930K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,603 | -21,187 |
| Depreciation expense | 153 | 347 |
| Noncash interest expense | 110 | 260 |
| Amortization of intangible assets | 95 | 190 |
| Net changes in operating lease rou assets and liabilities | -375 | 52 |
| Inventory excess and obsolescence charge | 632 | 910 |
| Stockbased compensation expense | 955 | 2,029 |
| Deferred income tax expense | 0 | 85 |
| Accounts receivable, net | 107 | 935 |
| Inventory | 838 | -610 |
| Prepaid expenses and other current assets | -272 | -14 |
| Accounts payable | 652 | -448 |
| Accrued expenses and other current and long-term liabilities | 633 | 464 |
| Foreign currency transaction loss | 48 | -83 |
| Net cash used in operating activities | -5,719 | -17,630 |
| Purchase of property and equipment | 211 | 146 |
| Proceeds from the sale of product line | 523 | 488 |
| Net cash provided by investing activities | 312 | 342 |
| Proceeds from exercise of stock options | 0 | 1 |
| Payment of withholding taxes related to stock-based compensation to employees | 21 | 180 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 45 | 60 |
| Net cash (used in) provided by financing activities | 24 | -119 |
| Effect of exchange rate on cash and cash equivalents | 104 | -286 |
| Net decrease in cash and cash equivalents and restricted cash | -5,279 | -17,693 |
| Cash and cash equivalents at beginning of period | 52,935 | - |
| Cash and cash equivalents at end of period | 29,963 | - |
TELA Bio, Inc. (TELA)
TELA Bio, Inc. (TELA)